BELEODAQ

This brand name is authorized in United States. It is also authorized in Brazil.

Active ingredients

The drug BELEODAQ contains one active pharmaceutical ingredient (API):

1	Belinostat UNII F4H96P17NZ - BELINOSTAT
	Belinostat is a histone deacetylase (HDAC) inhibitor. Belinostat shows preferential cytotoxicity towards tumor cells compared to normal cells. It is indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
	Read more about Belinostat

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BELEODAQ Powder for solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XH04		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XH Histone deacetylase (HDAC) inhibitors
Discover more medicines within L01XH04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	576120110000307
US	FDA, National Drug Code	68152-108, 72893-002